In this supplement to EMJ Hematology, two leading haematologists, Prof Adriano Venditti and Prof Lars Bullinger, discussed the management of patients with acute myeloid leukaemia (AML) and fms-related tyrosine kinase 3 (FLT3) gene mutations. Specifically, the roles for emerging treatment options and maintenance strategies in improving outcomes for patients with a FLT3 internal tandem duplication (ITD) mutation were explored.
EMJ Hematology 9 [Supplement 3] . 2021
June 2021
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/04/Niamh-OConnell-Thumbnail-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/03/Pier-Mannucci-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/03/Immunoglobin-D-Multiple-Myeloma-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/02/Coexistence-of-Sickle-Cell-Thalassaemia-with-Overlapping-Syndrome-940x564.png)